The Global Biological Skin Substitutes Market size is expected to reach $568.3 billion by 2031, rising at a market growth of 8.6% CAGR during the forecast period.
The North American market for biological skin substitutes leads globally, propelled by advanced healthcare infrastructure, significant investment in R&D, and a high prevalence of chronic wounds and burn injuries. Additionally, rising awareness about advanced wound care therapies and the continuous introduction of innovative products contribute to the segment's growth, making North America the dominant region for biological skin substitutes. Thus, the North America segment procured 40% revenue share in the biological skin substitutes market in 2023.
Chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, are often challenging to heal due to underlying health conditions like diabetes, poor circulation, and prolonged immobility. It is anticipated that 1 to 2 percent of the population in developed countries will endure a chronic wound at some point in their lives. Additionally, Reconstructive surgeries, often performed after trauma, burn injuries, cancer treatments, or congenital disabilities, also drive the demand for biological skin substitutes. Many patients undergoing reconstructive surgery require skin grafts to restore skin loss due to injury or illness, and biological substitutes offer an effective solution by promoting natural healing and minimizing visible scarring. Reconstructive surgeries, often performed after trauma, burn injuries, cancer treatments, or congenital disabilities, also drive the demand for biological skin substitutes. Many patients undergoing reconstructive surgery require skin grafts to restore skin loss due to injury or illness, and biological substitutes offer an effective solution by promoting natural healing and minimizing visible scarring.
However, biological skin substitutes significantly advance wound care and skin regeneration, providing a promising solution for burn victims and individuals with chronic wounds. However, one of the primary barriers to their widespread adoption is the high cost associated with these products. Developing biological skin substitutes requires sophisticated, cost-intensive manufacturing processes, including the harvesting, processing, and preserving of human or animal-derived tissues. Hence, the high cost of biological skin substitutes restricts their accessibility, limiting their impact on global health outcomes in wound care and skin regeneration.
Type Outlook
Based on type, the market is bifurcated into human donor tissue-derived products and acellular animal-derived products. The human donor tissue-derived products segment garnered 64% revenue share in the market in 2023. This segment leads the market due to its high compatibility and acceptance rates within the human body, which results in improved healing outcomes.
End Use Outlook
On the basis of end use, the market is classified into hospitals, outpatient facilities, and research & manufacturing. The hospitals segment acquired 53% revenue share in the market in 2023. This prominence is attributed to hospitals' comprehensive infrastructure and specialized medical personnel, enabling them to effectively manage complex wound care cases.
Application Outlook
By application, the market is divided into acute wounds and chronic wounds. The chronic wounds segment garnered 47% revenue share in the market in 2023. These wounds are often challenging to heal and require long-term management strategies. Biological skin substitutes offer effective solutions by providing a conducive environment for tissue regeneration and reducing healing time.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Europe segment acquired 30% revenue share in the market in 2023. The European market is driven by increasing awareness of advanced wound care solutions, a growing elderly population susceptible to chronic wounds, and proactive government initiatives supporting healthcare advancements.
List of Key Companies Profiled
- Smith & Nephew plc
- Stryker Corporation
- MIMEDX Group, Inc.
- Organogenesis Holdings, Inc.
- Integra LifeSciences Corporation
- 3M Company
- Essity AB (BSN Medical)
- Zimmer Biomet Holdings, Inc.
- Vericel Corporation
- Molnlycke Health Care AB
Global Biological Skin Substitutes Market Report Segmentation
By Type
- Human Donor Tissue-derived Products
- Acellular Animal-derived Products
By End Use
- Hospitals
- Outpatient Facilities
- Research & Manufacturing
By Application
- Acute Wounds
- Chronic Wounds
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Global Biological Skin Substitutes Market, by Type
- 1.4.2 Global Biological Skin Substitutes Market, by End Use
- 1.4.3 Global Biological Skin Substitutes Market, by Application
- 1.4.4 Global Biological Skin Substitutes Market, by Geography
- 1.5 Methodology for the research
Chapter 2. Market at a Glance
Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.2.3 Market Opportunities
- 3.2.4 Market Challenges
Chapter 4. Competition Analysis - Global
- 4.1 Market Share Analysis, 2023
- 4.2 Porter Five Forces Analysis
Chapter 5. Global Biological Skin Substitutes Market by Type
- 5.1 Global Human Donor Tissue-derived Products Market by Region
- 5.2 Global Acellular Animal-derived Products Market by Region
Chapter 6. Global Biological Skin Substitutes Market by End Use
- 6.1 Global Hospitals Market by Region
- 6.2 Global Outpatient Facilities Market by Region
- 6.3 Global Research & Manufacturing Market by Region
Chapter 7. Global Biological Skin Substitutes Market by Application
- 7.1 Global Acute Wounds Market by Region
- 7.2 Global Chronic Wounds Market by Region
Chapter 8. Global Biological Skin Substitutes Market by Region
- 8.1 North America Biological Skin Substitutes Market
- 8.1.1 North America Biological Skin Substitutes Market by Type
- 8.1.1.1 North America Human Donor Tissue-derived Products Market by Region
- 8.1.1.2 North America Acellular Animal-derived Products Market by Region
- 8.1.2 North America Biological Skin Substitutes Market by End Use
- 8.1.2.1 North America Hospitals Market by Country
- 8.1.2.2 North America Outpatient Facilities Market by Country
- 8.1.2.3 North America Research & Manufacturing Market by Country
- 8.1.3 North America Biological Skin Substitutes Market by Application
- 8.1.3.1 North America Acute Wounds Market by Country
- 8.1.3.2 North America Chronic Wounds Market by Country
- 8.1.4 North America Biological Skin Substitutes Market by Country
- 8.1.4.1 US Biological Skin Substitutes Market
- 8.1.4.1.1 US Biological Skin Substitutes Market by Type
- 8.1.4.1.2 US Biological Skin Substitutes Market by End Use
- 8.1.4.1.3 US Biological Skin Substitutes Market by Application
- 8.1.4.2 Canada Biological Skin Substitutes Market
- 8.1.4.2.1 Canada Biological Skin Substitutes Market by Type
- 8.1.4.2.2 Canada Biological Skin Substitutes Market by End Use
- 8.1.4.2.3 Canada Biological Skin Substitutes Market by Application
- 8.1.4.3 Mexico Biological Skin Substitutes Market
- 8.1.4.3.1 Mexico Biological Skin Substitutes Market by Type
- 8.1.4.3.2 Mexico Biological Skin Substitutes Market by End Use
- 8.1.4.3.3 Mexico Biological Skin Substitutes Market by Application
- 8.1.4.4 Rest of North America Biological Skin Substitutes Market
- 8.1.4.4.1 Rest of North America Biological Skin Substitutes Market by Type
- 8.1.4.4.2 Rest of North America Biological Skin Substitutes Market by End Use
- 8.1.4.4.3 Rest of North America Biological Skin Substitutes Market by Application
- 8.2 Europe Biological Skin Substitutes Market
- 8.2.1 Europe Biological Skin Substitutes Market by Type
- 8.2.1.1 Europe Human Donor Tissue-derived Products Market by Country
- 8.2.1.2 Europe Acellular Animal-derived Products Market by Country
- 8.2.2 Europe Biological Skin Substitutes Market by End Use
- 8.2.2.1 Europe Hospitals Market by Country
- 8.2.2.2 Europe Outpatient Facilities Market by Country
- 8.2.2.3 Europe Research & Manufacturing Market by Country
- 8.2.3 Europe Biological Skin Substitutes Market by Application
- 8.2.3.1 Europe Acute Wounds Market by Country
- 8.2.3.2 Europe Chronic Wounds Market by Country
- 8.2.4 Europe Biological Skin Substitutes Market by Country
- 8.2.4.1 Germany Biological Skin Substitutes Market
- 8.2.4.1.1 Germany Biological Skin Substitutes Market by Type
- 8.2.4.1.2 Germany Biological Skin Substitutes Market by End Use
- 8.2.4.1.3 Germany Biological Skin Substitutes Market by Application
- 8.2.4.2 UK Biological Skin Substitutes Market
- 8.2.4.2.1 UK Biological Skin Substitutes Market by Type
- 8.2.4.2.2 UK Biological Skin Substitutes Market by End Use
- 8.2.4.2.3 UK Biological Skin Substitutes Market by Application
- 8.2.4.3 France Biological Skin Substitutes Market
- 8.2.4.3.1 France Biological Skin Substitutes Market by Type
- 8.2.4.3.2 France Biological Skin Substitutes Market by End Use
- 8.2.4.3.3 France Biological Skin Substitutes Market by Application
- 8.2.4.4 Russia Biological Skin Substitutes Market
- 8.2.4.4.1 Russia Biological Skin Substitutes Market by Type
- 8.2.4.4.2 Russia Biological Skin Substitutes Market by End Use
- 8.2.4.4.3 Russia Biological Skin Substitutes Market by Application
- 8.2.4.5 Spain Biological Skin Substitutes Market
- 8.2.4.5.1 Spain Biological Skin Substitutes Market by Type
- 8.2.4.5.2 Spain Biological Skin Substitutes Market by End Use
- 8.2.4.5.3 Spain Biological Skin Substitutes Market by Application
- 8.2.4.6 Italy Biological Skin Substitutes Market
- 8.2.4.6.1 Italy Biological Skin Substitutes Market by Type
- 8.2.4.6.2 Italy Biological Skin Substitutes Market by End Use
- 8.2.4.6.3 Italy Biological Skin Substitutes Market by Application
- 8.2.4.7 Rest of Europe Biological Skin Substitutes Market
- 8.2.4.7.1 Rest of Europe Biological Skin Substitutes Market by Type
- 8.2.4.7.2 Rest of Europe Biological Skin Substitutes Market by End Use
- 8.2.4.7.3 Rest of Europe Biological Skin Substitutes Market by Application
- 8.3 Asia Pacific Biological Skin Substitutes Market
- 8.3.1 Asia Pacific Biological Skin Substitutes Market by Type
- 8.3.1.1 Asia Pacific Human Donor Tissue-derived Products Market by Country
- 8.3.1.2 Asia Pacific Acellular Animal-derived Products Market by Country
- 8.3.2 Asia Pacific Biological Skin Substitutes Market by End Use
- 8.3.2.1 Asia Pacific Hospitals Market by Country
- 8.3.2.2 Asia Pacific Outpatient Facilities Market by Country
- 8.3.2.3 Asia Pacific Research & Manufacturing Market by Country
- 8.3.3 Asia Pacific Biological Skin Substitutes Market by Application
- 8.3.3.1 Asia Pacific Acute Wounds Market by Country
- 8.3.3.2 Asia Pacific Chronic Wounds Market by Country
- 8.3.4 Asia Pacific Biological Skin Substitutes Market by Country
- 8.3.4.1 China Biological Skin Substitutes Market
- 8.3.4.1.1 China Biological Skin Substitutes Market by Type
- 8.3.4.1.2 China Biological Skin Substitutes Market by End Use
- 8.3.4.1.3 China Biological Skin Substitutes Market by Application
- 8.3.4.2 Japan Biological Skin Substitutes Market
- 8.3.4.2.1 Japan Biological Skin Substitutes Market by Type
- 8.3.4.2.2 Japan Biological Skin Substitutes Market by End Use
- 8.3.4.2.3 Japan Biological Skin Substitutes Market by Application
- 8.3.4.3 India Biological Skin Substitutes Market
- 8.3.4.3.1 India Biological Skin Substitutes Market by Type
- 8.3.4.3.2 India Biological Skin Substitutes Market by End Use
- 8.3.4.3.3 India Biological Skin Substitutes Market by Application
- 8.3.4.4 South Korea Biological Skin Substitutes Market
- 8.3.4.4.1 South Korea Biological Skin Substitutes Market by Type
- 8.3.4.4.2 South Korea Biological Skin Substitutes Market by End Use
- 8.3.4.4.3 South Korea Biological Skin Substitutes Market by Application
- 8.3.4.5 Singapore Biological Skin Substitutes Market
- 8.3.4.5.1 Singapore Biological Skin Substitutes Market by Type
- 8.3.4.5.2 Singapore Biological Skin Substitutes Market by End Use
- 8.3.4.5.3 Singapore Biological Skin Substitutes Market by Application
- 8.3.4.6 Malaysia Biological Skin Substitutes Market
- 8.3.4.6.1 Malaysia Biological Skin Substitutes Market by Type
- 8.3.4.6.2 Malaysia Biological Skin Substitutes Market by End Use
- 8.3.4.6.3 Malaysia Biological Skin Substitutes Market by Application
- 8.3.4.7 Rest of Asia Pacific Biological Skin Substitutes Market
- 8.3.4.7.1 Rest of Asia Pacific Biological Skin Substitutes Market by Type
- 8.3.4.7.2 Rest of Asia Pacific Biological Skin Substitutes Market by End Use
- 8.3.4.7.3 Rest of Asia Pacific Biological Skin Substitutes Market by Application
- 8.4 LAMEA Biological Skin Substitutes Market
- 8.4.1 LAMEA Biological Skin Substitutes Market by Type
- 8.4.1.1 LAMEA Human Donor Tissue-derived Products Market by Country
- 8.4.1.2 LAMEA Acellular Animal-derived Products Market by Country
- 8.4.2 LAMEA Biological Skin Substitutes Market by End Use
- 8.4.2.1 LAMEA Hospitals Market by Country
- 8.4.2.2 LAMEA Outpatient Facilities Market by Country
- 8.4.2.3 LAMEA Research & Manufacturing Market by Country
- 8.4.3 LAMEA Biological Skin Substitutes Market by Application
- 8.4.3.1 LAMEA Acute Wounds Market by Country
- 8.4.3.2 LAMEA Chronic Wounds Market by Country
- 8.4.4 LAMEA Biological Skin Substitutes Market by Country
- 8.4.4.1 Brazil Biological Skin Substitutes Market
- 8.4.4.1.1 Brazil Biological Skin Substitutes Market by Type
- 8.4.4.1.2 Brazil Biological Skin Substitutes Market by End Use
- 8.4.4.1.3 Brazil Biological Skin Substitutes Market by Application
- 8.4.4.2 Argentina Biological Skin Substitutes Market
- 8.4.4.2.1 Argentina Biological Skin Substitutes Market by Type
- 8.4.4.2.2 Argentina Biological Skin Substitutes Market by End Use
- 8.4.4.2.3 Argentina Biological Skin Substitutes Market by Application
- 8.4.4.3 UAE Biological Skin Substitutes Market
- 8.4.4.3.1 UAE Biological Skin Substitutes Market by Type
- 8.4.4.3.2 UAE Biological Skin Substitutes Market by End Use
- 8.4.4.3.3 UAE Biological Skin Substitutes Market by Application
- 8.4.4.4 Saudi Arabia Biological Skin Substitutes Market
- 8.4.4.4.1 Saudi Arabia Biological Skin Substitutes Market by Type
- 8.4.4.4.2 Saudi Arabia Biological Skin Substitutes Market by End Use
- 8.4.4.4.3 Saudi Arabia Biological Skin Substitutes Market by Application
- 8.4.4.5 South Africa Biological Skin Substitutes Market
- 8.4.4.5.1 South Africa Biological Skin Substitutes Market by Type
- 8.4.4.5.2 South Africa Biological Skin Substitutes Market by End Use
- 8.4.4.5.3 South Africa Biological Skin Substitutes Market by Application
- 8.4.4.6 Nigeria Biological Skin Substitutes Market
- 8.4.4.6.1 Nigeria Biological Skin Substitutes Market by Type
- 8.4.4.6.2 Nigeria Biological Skin Substitutes Market by End Use
- 8.4.4.6.3 Nigeria Biological Skin Substitutes Market by Application
- 8.4.4.7 Rest of LAMEA Biological Skin Substitutes Market
- 8.4.4.7.1 Rest of LAMEA Biological Skin Substitutes Market by Type
- 8.4.4.7.2 Rest of LAMEA Biological Skin Substitutes Market by End Use
- 8.4.4.7.3 Rest of LAMEA Biological Skin Substitutes Market by Application
Chapter 9. Company Profiles
- 9.1 Smith & Nephew PLC
- 9.1.1 Company Overview
- 9.1.2 Financial Analysis
- 9.1.3 Regional and Segmental Analysis
- 9.1.4 Research & Development Expense
- 9.1.5 SWOT Analysis
- 9.2 Stryker Corporation
- 9.2.1 Company Overview
- 9.2.2 Financial Analysis
- 9.2.3 Segmental and Regional Analysis
- 9.2.4 Research & Development Expenses
- 9.2.5 SWOT Analysis
- 9.3 MiMedx Group. Inc.
- 9.3.1 Company Overview
- 9.3.2 Financial Analysis
- 9.3.3 Research & Development Expenses
- 9.3.4 SWOT Analysis
- 9.4 Organogenesis Holdings, Inc.
- 9.4.1 Company Overview
- 9.4.2 Financial Analysis
- 9.4.3 Research & Development Expenses
- 9.5 Integra LifeSciences Holdings Corporation
- 9.5.1 Company Overview
- 9.5.2 Financial Analysis
- 9.5.3 Segmental and Regional Analysis
- 9.5.4 Research & Development Expenses
- 9.5.5 SWOT Analysis
- 9.6 3M Company
- 9.6.1 Company Overview
- 9.6.2 Financial Analysis
- 9.6.3 Segmental and Regional Analysis
- 9.6.4 Research & Development Expense
- 9.6.5 SWOT Analysis
- 9.7 Essity AB (BSN medical)
- 9.7.1 Company Overview
- 9.7.2 Financial Analysis
- 9.7.3 Segmental and Regional Analysis
- 9.7.4 Research & Development Expenses
- 9.7.5 SWOT Analysis
- 9.8 Zimmer Biomet Holdings, Inc.
- 9.8.1 Company Overview
- 9.8.2 Financial Analysis
- 9.8.3 Segmental and Regional Analysis
- 9.8.4 Research & Development Expense
- 9.8.5 SWOT Analysis
- 9.9 Vericel Corporation
- 9.9.1 Company Overview
- 9.9.2 Financial Analysis
- 9.9.3 Research & Development Expense
- 9.9.4 SWOT Analysis
- 9.10. Molnlycke Health Care AB
- 9.10.1 Company Overview
- 9.10.2 SWOT Analysis
Chapter 10. Winning Imperatives of Biological Skin Substitutes Market